Valneva's chikungunya vaccine keeps antibodies strong in all age groups, helping its vaccination plans.

VALN · Valneva SE

The AI's read

These findings strengthen the case for IXCHIQ and may help support its use. The Brazil pilot shows vaccination on a large scale, but the report gives no sales or disease-prevention results. The findings favor Valneva, though they do not prove wider demand or real-world protection.